Advertisement

Journal of Neuro-Oncology

, Volume 131, Issue 3, pp 611–618 | Cite as

Comparing pre-operative stereotactic radiosurgery (SRS) to post-operative whole brain radiation therapy (WBRT) for resectable brain metastases: a multi-institutional analysis

  • Kirtesh R. PatelEmail author
  • Stuart H. Burri
  • Danielle Boselli
  • James T. Symanowski
  • Anthony L. Asher
  • Ashley Sumrall
  • Robert W. Fraser
  • Robert H. Press
  • Jim Zhong
  • Richard J. Cassidy
  • Jeffrey J. Olson
  • Walter J. Curran
  • Hui-Kuo G. Shu
  • Ian R. Crocker
  • Roshan S. Prabhu
Clinical Study

Abstract

Pre-operative stereotactic radiosurgery (pre-SRS) has been shown as a viable treatment option for resectable brain metastases (BM). The aim of this study is to compare oncologic outcomes and toxicities for pre-SRS and post-operative WBRT (post-WBRT) for resectable BM. We reviewed records of consecutive patients who underwent resection of BM and either pre-SRS or post-WBRT between 2005 and 2013 at two institutions. Overall survival (OS) was calculated using the Kaplan–Meier method. Cumulative incidence was used for intracranial outcomes. Multivariate analysis (MVA) was performed using the Cox and Fine and Gray models, respectively. Overall, 102 patients underwent surgical resection of BM; 66 patients with 71 lesions received pre-SRS while 36 patients with 42 cavities received post-WBRT. Baseline characteristics were similar except for the pre-SRS cohort having more single lesions (65.2% vs. 38.9%, p = 0.001) and smaller median lesion volume (8.3 cc vs. 15.3 cc, p = 0.006). 1-year OS was similar between cohorts (58% vs. 56%, respectively) (p = 0.43). Intracranial outcomes were also similar (2-year outcomes, pre-SRS vs. post-WBRT): local recurrence: 24.5% vs. 25% (p = 0.81), distant brain failure (DBF): 53.2% vs. 45% (p = 0.66), and leptomeningeal disease (LMD) recurrence: 3.5% vs. 9.0% (p = 0.66). On MVA, radiation cohort was not independently associated with OS or any intracranial outcome. Crude rates of symptomatic radiation necrosis were 5.6 and 0%, respectively. OS and intracranial outcomes were similar for patients treated with pre-SRS or post-WBRT for resected BM. Pre-SRS is a viable alternative to post-WBRT for resected BM. Further confirmatory studies with neuro-cognitive outcomes comparing these two treatment paradigms are needed.

Keywords

Brain metastases Resection Pre-operative Post-operative Stereotactic radiosurgery Whole brain radiation therapy 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Collette S, Collette L, Mueller RP (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. J Clin Oncol 29(2):134–141. doi: 10.1200/JCO.2010.30.1655 CrossRefPubMedGoogle Scholar
  2. 2.
    Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280(17):1485–1489CrossRefPubMedGoogle Scholar
  3. 3.
    Patel KR, Lawson DH, Kudchadkar RR, Carthon BC, Oliver DE, Okwan-Duodu D, Ahmed R, Khan MK (2015) Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro Oncol 17(10):1312–1321. doi: 10.1093/neuonc/nov093 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10(11):1037–1044. doi: 10.1016/S1470-2045(09)70263-3 CrossRefPubMedGoogle Scholar
  5. 5.
    Brown PD, Asher AL, Ballman KV, Farace E, Cerhan JH, Anderson SK, Carrero XW, Barker FG, Deming RL, Burri S (2015) NCCTG N0574 (Alliance): a phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. In: ASCO Annual Meeting Proceedings, 2015 vol 15_suppl. p LBA4Google Scholar
  6. 6.
    Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295(21):2483–2491. doi: 10.1001/jama.295.21.2483 CrossRefPubMedGoogle Scholar
  7. 7.
    Patel KR, Prabhu RS, Kandula S, Oliver DE, Kim S, Hadjipanayis C, Olson JJ, Oyesiku N, Curran WJ, Khan MK, Shu HK, Crocker I (2014) Intracranial control and radiographic changes with adjuvant radiation therapy for resected brain metastases: whole brain radiotherapy versus stereotactic radiosurgery alone. J Neurooncol 120(3):657–663. doi: 10.1007/s11060-014-1601-4 CrossRefPubMedGoogle Scholar
  8. 8.
    Suki D, Hatiboglu MA, Patel AJ, Weinberg JS, Groves MD, Mahajan A, Sawaya R (2009) Comparative risk of leptomeningeal dissemination of cancer after surgery or stereotactic radiosurgery for a single supratentorial solid tumor metastasis. Neurosurgery 64 (4):664–674 (discussion 674-666). doi: 10.1227/01.NEU.0000341535.53720.3E CrossRefPubMedGoogle Scholar
  9. 9.
    Asher AL, Burri SH, Wiggins WF, Kelly RP, Boltes MO, Mehrlich M, Norton HJ, Fraser RW (2014) A new treatment paradigm: neoadjuvant radiosurgery before surgical resection of brain metastases with analysis of local tumor recurrence. Int J Radiat Oncol Biol Phys 88(4):899–906. doi: 10.1016/j.ijrobp.2013.12.013 CrossRefPubMedGoogle Scholar
  10. 10.
    Blonigen BJ, Steinmetz RD, Levin L, Lamba MA, Warnick RE, Breneman JC (2010) Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 77(4):996–1001. doi: 10.1016/j.ijrobp.2009.06.006 CrossRefPubMedGoogle Scholar
  11. 11.
    Minniti G, Clarke E, Lanzetta G, Osti MF, Trasimeni G, Bozzao A, Romano A, Enrici RM (2011) Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol 6:48. doi: 10.1186/1748-717X-6-48 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Patel KR, Burri SH, Asher AL, Crocker IR, Fraser RW, Zhang C, Chen Z, Kandula S, Zhong J, Press RH, Olson JJ, Oyesiku NM, Wait SD, Curran WJ, Shu HG, Prabhu RS (2015) Comparing preoperative with postoperative stereotactic radiosurgery for resectable brain metastases: a multi-institutional analysis. Neurosurgery. doi: 10.1227/NEU.0000000000001096 Google Scholar
  13. 13.
    Shaw E, Scott C, Souhami L, Dinapoli R, Bahary JP, Kline R, Wharam M, Schultz C, Davey P, Loeffler J, Del Rowe J, Marks L, Fisher B, Shin K (1996) Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: initial report of radiation therapy oncology group protocol (90-05). Int J Radiat Oncol Biol Phys 34(3):647–654CrossRefPubMedGoogle Scholar
  14. 14.
    Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70(2):510–514. doi: 10.1016/j.ijrobp.2007.06.074 CrossRefPubMedGoogle Scholar
  15. 15.
    Kumar AJ, Leeds NE, Fuller GN, Van Tassel P, Maor MH, Sawaya RE, Levin VA (2000) Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217(2):377–384. doi: 10.1148/radiology.217.2.r00nv36377 CrossRefPubMedGoogle Scholar
  16. 16.
    Kalbfleisch JD, Ross LP (2002) The statistical analysis of failure time data. Wiley series in probability and statistics, 2nd edn. Wiley, New YorkCrossRefGoogle Scholar
  17. 17.
    Cox DR (1972) Regression models and life tables. J Royal Stat Soc B34:187–220Google Scholar
  18. 18.
    Sahgal A, Aoyama H, Kocher M, Neupane B, Collette S, Tago M, Shaw P, Beyene J, Chang EL (2015) Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 91(4):710–717. doi: 10.1016/j.ijrobp.2014.10.024 CrossRefPubMedGoogle Scholar
  19. 19.
    Johnson MD, Avkshtol V, Baschnagel AM, Meyer K, Ye H, Grills IS, Chen PY, Maitz A, Olson RE, Pieper DR, Krauss DJ (2016) Surgical resection of brain metastases and the risk of leptomeningeal recurrence in patients treated with stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 94(3):537–543. doi: 10.1016/j.ijrobp.2015.11.022 CrossRefPubMedGoogle Scholar
  20. 20.
    Atalar B, Modlin LA, Choi CY, Adler JR, Gibbs IC, Chang SD, Harsh GRt, Li G, Nagpal S, Hanlon A, Soltys SG (2013) Risk of leptomeningeal disease in patients treated with stereotactic radiosurgery targeting the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys 87(4):713–718. doi: 10.1016/j.ijrobp.2013.07.034 CrossRefPubMedGoogle Scholar
  21. 21.
    Ojerholm E, Lee JY, Thawani JP, Miller D, O’Rourke DM, Dorsey JF, Geiger GA, Nagda S, Kolker JD, Lustig RA, Alonso-Basanta M (2014) Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis. J Neurosurg 121(Suppl 2):75–83. doi: 10.3171/2014.6.GKS14708 PubMedGoogle Scholar
  22. 22.
    Hyun JW, Jeong IH, Joung A, Cho HJ, Kim SH, Kim HJ (2016) Leptomeningeal metastasis: clinical experience of 519 cases. Eur J Cancer 56:107–114. doi: 10.1016/j.ejca.2015.12.021 CrossRefPubMedGoogle Scholar
  23. 23.
    Huang AJ, Huang KE, Page BR, Ayala-Peacock DN, Lucas JT Jr, Lesser GJ, Laxton AW, Tatter SB, Chan MD (2014) Risk factors for leptomeningeal carcinomatosis in patients with brain metastases who have previously undergone stereotactic radiosurgery. J Neurooncol 120(1):163–169. doi: 10.1007/s11060-014-1539-6 CrossRefPubMedGoogle Scholar
  24. 24.
    Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, Schnell P, Wilner KD, Wiltshire R, Camidge DR, Crino L (2015) Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33(17):1881–1888. doi: 10.1200/JCO.2014.59.0539 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087–1095. doi: 10.1016/S1470-2045(12)70431-X CrossRefPubMedGoogle Scholar
  26. 26.
    Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459–465. doi: 10.1016/S1470-2045(12)70090-6 CrossRefPubMedGoogle Scholar
  27. 27.
    Patel KR, Shoukat S, Oliver DE, Chowdhary M, Rizzo M, Lawson DH, Khosa F, Liu Y, Khan MK (2015) Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol. doi: 10.1097/COC.0000000000000199 PubMedCentralGoogle Scholar
  28. 28.
    Patel KR, Chowdhary M, Switchenko JM, Kudchadkar R, Lawson DH, Cassidy RJ, Prabhu RS, Khan MK (2016) BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res 26(4):387–394. doi: 10.1097/CMR.0000000000000268 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Kirtesh R. Patel
    • 1
    Email author
  • Stuart H. Burri
    • 2
  • Danielle Boselli
    • 3
  • James T. Symanowski
    • 3
  • Anthony L. Asher
    • 4
  • Ashley Sumrall
    • 5
  • Robert W. Fraser
    • 2
  • Robert H. Press
    • 1
  • Jim Zhong
    • 1
  • Richard J. Cassidy
    • 1
  • Jeffrey J. Olson
    • 6
  • Walter J. Curran
    • 1
  • Hui-Kuo G. Shu
    • 1
  • Ian R. Crocker
    • 1
  • Roshan S. Prabhu
    • 2
  1. 1.Department of Radiation Oncology, Winship Cancer InstituteEmory UniversityAtlantaUSA
  2. 2.Southeast Radiation Oncology Group, Levine Cancer InstituteCarolinas Healthcare SystemCharlotteUSA
  3. 3.Department of Cancer Biostatistics, Levine Cancer InstituteCarolinas Healthcare SystemCharlotteUSA
  4. 4.Carolina Neurosurgery and Spine AssociatesLevine Cancer InstituteCharlotteUSA
  5. 5.Department of Oncology, Levine Cancer InstituteCarolinas Healthcare SystemCharlotteUSA
  6. 6.Department of Neurosurgery and Winship Cancer InstituteEmory UniversityAtlantaUSA

Personalised recommendations